



March 30, 2026

National Stock Exchange of India Limited

Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
Mumbai - 400 051

BSE Limited

P. J. Towers, Dalal Street,
Mumbai Samachar Marg,
Mumbai - 400 001

Symbol: LUPIN

Scrip Code: Equity – 500257

Subject: Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations')

Dear Sir/Madam,

Pursuant to Regulation 30 read with Schedule III of the SEBI Listing Regulations, we are pleased to inform you that Multicare Pharmaceuticals Philippines, Inc. ('MPPI'), a subsidiary of Nanomi B.V., the Netherlands ('Nanomi'), which is a wholly owned subsidiary of the Company, has bought back 2,813,811 equity shares from some of its existing shareholders. Nanomi did not participate in the said buyback. This has resulted in increase in the shareholding of Nanomi in MPPI from 51% to 56.28% effective today.

The details required under Regulation 30 and Schedule III of SEBI Listing Regulations, read with the SEBI Master Circular dated January 30, 2026, bearing reference number HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 and such other circulars as applicable ('SEBI Master Circular'), is set out below at **Annexure I.**

The above is for your information and dissemination.

Thanking you,

For LUPIN LIMITED

**AMIT KUMAR GUPTA
COMPANY SECRETARY & COMPLIANCE OFFICER
(ACS -15754)**

Encl: a/a.



Annexure I

Disclosure as per Regulation 30 of SEBI Listing Regulations read with SEBI Master Circular.

Sr. No.	Particulars	Details
1.	Name of the target entity, details in brief such as size, turnover etc.;	<p>(i) <u>Name of the Target entity:</u> Multicare Pharmaceuticals Philippines, Inc. ('MPPI').</p> <p>(ii) <u>Details of Target entity:</u> MPPI is headquartered in Philippines and is engaged in trading, importing, marketing, and distributing pharmaceutical products and medical devices.</p> <p>(iii) <u>Financial details:</u> The financial details of MPPI as on March 31, 2025, are as under: 1. Turnover: PHP 2,096.6 million. 2. Net Worth: PHP 1,265.5 million.</p>
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length";	<p>The said buyback does not fall within the purview of related party transactions.</p> <p>None of the promoter/promoter group/group companies have any interest in the proposed buyback.</p>
3.	Industry to which the entity being acquired belongs;	Pharmaceuticals.
4.	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	Not applicable, as MPPI has bought back 2,813,811 equity shares from some of its existing shareholders by utilizing its retained earnings, wherein Nanomi did not participate in the buyback. This has consequently resulted in increase in the shareholding of Nanomi in MPPI from 51% to 56.28% effective today.
5.	Brief details of any governmental or regulatory approvals required for the acquisition.	Not applicable.
6.	Indicative time period for completion of the acquisition;	Shareholding of Nanomi in MPPI has increased from 51% to 56.28% effective today.
7.	Consideration - whether cash consideration or share swap or any other form and details of the same;	Not applicable, as Nanomi did not participate in the buyback.



LUPIN

8.	Cost of acquisition and/or the price at which the shares are acquired;	Not applicable.
9.	Percentage of shareholding / control acquired and / or number of shares acquired;	Pursuant to the buyback of 2,813,811 equity shares by MPPI from some of its existing shareholders, the shareholding of Nanomi in MPPI has increased from 51% to 56.28% effective today.
10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief):	<p>(i) <u>Brief Background:</u> Please refer to point no. 1 (ii).</p> <p>(ii) <u>Date of Incorporation:</u> November 09, 2001.</p> <p>(iii) <u>Country in which the acquired entity has presence:</u> Not applicable.</p> <p>(i) <u>Turnover for the last 3 years:</u> FY 25: PHP 2,096.6 million. FY 24: PHP 2,351.2 million. FY 23: PHP 1,744.7 million.</p>